LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

Начало・Списък с акции・Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

18.37 0.11

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

18.05

Максимум

18.52

Ключови измерители
By Trading Economics
Приходи	25M -43M
Продажби	-3.6M 65M
EPS	-0.48
Марж на печалбата	-65.788
Служители	298
EBITDA	-16M -31M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+110.28% upside

Дивиденти
By Dow Jones
Следващи печалби	3.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-182M 1.7B
Предишно отваряне	18.26
Предишно затваряне	18.37

Настроения в новините

By Acuity

27%

73%

69 / 344 Класиране в Healthcare

Syndax Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

3.06.2026 г., 23:22 ч. UTC

Печалби

Значими двигатели на пазара

Broadcom Shares Slide Despite Jump in 2Q Revenue on AI Chip Demand -- Update

3.06.2026 г., 23:09 ч. UTC

Горещи акции

Stocks to Watch: Broadcom, CrowdStrike, PVH, Petco

3.06.2026 г., 20:51 ч. UTC

Печалби

Costco Reports 15% Sales Growth in May

3.06.2026 г., 20:43 ч. UTC

Печалби

Broadcom 2Q Revenue Climbs on AI Chip Demand

3.06.2026 г., 23:48 ч. UTC

Пазарно говорене

Nikkei May Fall Amid Renewed Concerns About Iran Conflict -- Market Talk

3.06.2026 г., 23:48 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

3.06.2026 г., 23:35 ч. UTC

Пазарно говорене

Oil Futures Fall on Possible Technical Correction -- Market Talk

3.06.2026 г., 23:15 ч. UTC

Пазарно говорене

Печалби

Five Below, Broadcom and Crowdstrike Fall Despite Solid Results -- Market Talk

3.06.2026 г., 22:08 ч. UTC

Горещи акции

After-Hours Stocks to Watch: CrowdStrike, Broadcom, Five Below -- WSJ

3.06.2026 г., 21:54 ч. UTC

Пазарно говорене

Correction to Oil Futures Rise on Concerns About U.S.-Iran Talks Article on June 1

3.06.2026 г., 21:18 ч. UTC

Печалби

Broadcom's Non-AI Semiconductor Revenue Rose 6% in 2Q, CEO Says

3.06.2026 г., 21:15 ч. UTC

Печалби

Broadcom CEO: Google Partnership Continues to Be 'Very Substantial'

3.06.2026 г., 21:13 ч. UTC

Печалби

Broadcom CEO Expects AI Semiconductor Revenue Growth to Continue in Fiscal 2028

3.06.2026 г., 21:13 ч. UTC

Печалби

Broadcom Continues to Expect AI Semiconductor Revenue of More Than $100B in 2027, CEO Says

3.06.2026 г., 21:12 ч. UTC

Печалби

Broadcom Expects AI Semiconductor Revenue of $56B This Year, CEO Says

3.06.2026 г., 21:09 ч. UTC

Печалби

Broadcom CEO: Networking Made Up Almost 40% of AI Revenue in 2Q

3.06.2026 г., 21:03 ч. UTC

Печалби

Broadcom Stock Falls After Earnings. Here's Why. -- Barrons.com

3.06.2026 г., 20:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

3.06.2026 г., 20:43 ч. UTC

Печалби

CrowdStrike Stock Falls Despite Earnings Beat -- Barrons.com

3.06.2026 г., 20:39 ч. UTC

Придобивния, сливания и поглъщания

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 4th Update

3.06.2026 г., 20:37 ч. UTC

Придобивния, сливания и поглъщания

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 3rd Update

3.06.2026 г., 20:35 ч. UTC

Печалби

Broadcom Stock Falls Despite Record Results -- Barrons.com

3.06.2026 г., 20:21 ч. UTC

Придобивния, сливания и поглъщания

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 2nd Update

3.06.2026 г., 20:17 ч. UTC

Печалби

Broadcom 2Q Semiconductor Solutions Revenue $15B >AVGO

3.06.2026 г., 20:17 ч. UTC

Печалби

Broadcom Sees 3Q Semiconductor Revenue From AI $16B >AVGO

3.06.2026 г., 20:15 ч. UTC

Придобивния, сливания и поглъщания

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- Update

3.06.2026 г., 20:15 ч. UTC

Печалби

Broadcom 2Q Adj EPS $2.44 >AVGO

3.06.2026 г., 20:15 ч. UTC

Печалби

Broadcom 2Q EPS $1.91 >AVGO

3.06.2026 г., 20:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

3.06.2026 г., 20:15 ч. UTC

Печалби

Broadcom 2Q Rev $22.19B >AVGO

Сравнение с други в отрасъла

Ценова промяна

Syndax Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

110.28% нагоре

12-месечна прогноза

Среден 38.67 USD 110.28%

Висок 46 USD

Нисък 29 USD

Според 10 анализатори от Wall Street, предложили 12-месечна ценова цел за Syndax Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

10 ratings

Купи

Задържане

Продай

Според 10 анализатори, дали борсови рейтинги на Syndax Pharmaceuticals Inc през последните 3 месеца.

Настроение

By Acuity

69 / 344 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.